Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioLineRx (BLRX) EBITDA Margin: 2023-2025

Historic EBITDA Margin for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to 1,296.05%.

  • BioLineRx's EBITDA Margin rose 128708.00% to 1,296.05% in Q2 2025 from the same period last year, while for Jun 2025 it was -4.32%, marking a year-over-year increase of 25187.00%. This contributed to the annual value of -70.52% for FY2024, which is 96477.00% up from last year.
  • Latest data reveals that BioLineRx reported EBITDA Margin of 1,296.05% as of Q2 2025, which was down 35.54% from 2,010.59% recorded in Q1 2025.
  • BioLineRx's 5-year EBITDA Margin high stood at 2,010.59% for Q1 2025, and its period low was -1,476.34% during Q3 2023.
  • Its 3-year average for EBITDA Margin is 374.96%, with a median of -0.59% in 2024.
  • As far as peak fluctuations go, BioLineRx's EBITDA Margin plummeted by 202,973bps in 2024, and later soared by 202,074bps in 2025.
  • Over the past 3 years, BioLineRx's EBITDA Margin (Quarterly) stood at 1,992.06% in 2023, then plummeted by 202,973bps to -37.67% in 2024, then soared by 128,708bps to 1,296.05% in 2025.
  • Its EBITDA Margin stands at 1,296.05% for Q2 2025, versus 2,010.59% for Q1 2025 and -37.67% for Q4 2024.